Allison Dorval
2021 - Verve Therapeutics
In 2021, Allison Dorval earned a total compensation of $3.3M as Chief Financial Officer at Verve Therapeutics.
Compensation breakdown
Non-Equity Incentive Plan | $22,890 |
---|---|
Option Awards | $3,014,145 |
Salary | $39,545 |
Stock Awards | $249,375 |
Other | $769 |
Total | $3,326,724 |
Dorval received $3M in option awards, accounting for 91% of the total pay in 2021.
Dorval also received $22.9K in non-equity incentive plan, $39.5K in salary, $249.4K in stock awards and $769 in other compensation.
Rankings
In 2021, Allison Dorval's compensation ranked 4,019th out of 12,415 executives tracked by ExecPay. In other words, Dorval earned more than 67.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 4,019 | 68th |
Manufacturing | 1,647 | 70th |
Chemicals And Allied Products | 682 | 71st |
Drugs | 605 | 71st |
Pharmaceutical Preparations | 424 | 73rd |
Dorval's colleagues
We found two more compensation records of executives who worked with Allison Dorval at Verve Therapeutics in 2021.